Mast Cell Chymase antibody | CC1
No associated image currently available
Mouse anti Human Mast Cell Chymase antibody, clone CC1 binds to human mast cell chymase, an important marker of mast cells and also an important mediator of inflammation.
Mouse anti Human Mast Cell Chymase antibody, clone CC1 may be used to detect mast cells in routinely fixed tissues, and has been used to study the distribution of mast cells in skin, synovium, lung and heart.
Binding of Mouse anti Human Mast Cell Chymase antibody, clone CC1 to chymase is not reduced in the presence of heparin, suggesting that the antibody does not bind to the heparin-binding domain of chymase.
Mouse anti Human Mast Cell Chymase antibody, clone CC1 may be used to detect mast cells in routinely fixed tissues, and has been used to study the distribution of mast cells in skin, synovium, lung and heart.
Binding of Mouse anti Human Mast Cell Chymase antibody, clone CC1 to chymase is not reduced in the presence of heparin, suggesting that the antibody does not bind to the heparin-binding domain of chymase.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide - Carrier Free
- Yes
- Immunogen
- Purified human skin chymase.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the P3/NSI/I.Ag4.1 mouse myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 18 months from date of despatch.
More Information
- UniProt
- P23946 Related reagents
- Entrez Gene
- CMA1 Related reagents
- GO Terms
- GO:0004252 serine-type endopeptidase activity
- GO:0005576 extracellular region
- GO:0006508 proteolysis
- GO:0050720 interleukin-1 beta biosynthetic process
- GO:0050727 regulation of inflammatory response
- Regulatory
- For research purposes only
Applications of Mast Cell Chymase antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| Immunohistology - Frozen | |||
| Immunohistology - Paraffin | 1/500 | 1ug/ml Pack Size: 10 µg 1/1000 Pack Size: 0.1 mg |
|
| Western Blotting |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Immunohistology
- This product does not require protein digestion pre-treatment of paraffin sections. This product does not require antigen retrieval using heat treatment prior to staining of paraffin sections.
- Histology Positive Control Tissue
- Skin
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Application Based External Images
ELISA
Immunohistology - Frozen
Immunohistology - Paraffin
Western Blotting
Product Specific References
Source Reference
-
Buckley, M.G. et al. (1999) The detection of mast cell subpopulations in formalin-fixed human tissues using a new monoclonal antibody specific for chymase.
J Pathol. 189 (1): 138-43.
References for Mast Cell Chymase antibody
-
Mauro, L.V. et al. (2008) Association between mast cells of different phenotypes and angiogenesis in colorectal cancer.
Mol Med Rep. 1 (6): 895-902. -
Dougherty, R.H. et al. (2010) Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma.
J Allergy Clin Immunol. 125 (5): 1046-1053.e8. -
Xiang, M. et al. (2011) Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population.
Atherosclerosis. 215 (2): 494-9. -
Sun, J. et al. (2009) Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation.
Circulation. 120: 973-82. -
Laidlaw, T.M. et al. (2011) Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.
J Allergy Clin Immunol. 127: 815-22.e1-5. -
Lin, A.M. et al. (2011) Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis.
J Immunol. 187: 490-500. -
Veerappan, A. et al. (2012) Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model.
Am J Physiol Renal Physiol. 302 (1): F192-204. -
Buckley, M. Walls, A.F. (2008) Identification of mast cells and mast cell subpopulations.
Methods Mol Med. 138: 285-97. -
Bhattacharya, S. et al. (2012) Genome-wide transcriptional profiling reveals connective tissue mast cell accumulation in bronchopulmonary dysplasia.
Am J Respir Crit Care Med. 186: 349-58. -
Martin, L.J. et al. (2015) Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.
J Allergy Clin Immunol. 135 (6): 1519-28.e8. -
Badertscher, K. et al. (2005) Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis.
Arch Dermatol Res. 296 (10): 503-6. -
Allam, J.P. et al. (2008) Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?
Allergy. 63 (6): 720-7. -
Galatowicz, G. et al. (2007) Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Clin Exp Allergy. 37 (11): 1648-56. -
Lipitsä, T. et al. (2015) Mast cell tryptase and chymase in the progress of cutaneous vasculitis.
Arch Dermatol Res. 307 (10): 917-24. -
Suttle, M.M. & Harvima, I.T. (2016) Mast cell chymase in experimentally induced psoriasis.
J Dermatol. 43 (6): 693-6.
